Phase 4 N=66,228 Mortality Reduction After Oral Azithromycin Contingency: Mortality Study
Childhood Mortality
Primary: All-cause Mortality Rate in Children Aged 1-60 Months — 24.8; 26.7 deaths per 1000 person years
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=433 Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers
Smoking Cessation
Primary: Time to First Quit Attempt — 0.89; 1.48 days — p=0.02
Phase 3 N=164 HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Amyloidosis, Hereditary · Transthyretin Amyloidosis
Primary: Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group…
Phase 2 N=129 Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Primary: Phase 1b Primary Safety Outcome — 6; 6; 6; 6 Participants
Phase 2 N=21 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
Non-small Cell Lung Cancer · Non Small Cell Lung Cancer · NSCLC
Primary: Overall Response Rate (ORR) — 1 Participants
Phase 3 N=2,722 Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
Breast Cancer
Primary: Disease Free Survival — 80.1; 79.4 percentage of participants
N/A N=91 The Long-Term Treatment of Drug Addiction and Unemployment
Substance Abuse, Intravenous
Primary: The Percentage of Opiate- and Cocaine-negative Urine Samples — 44.9; 64.6 percentage of urine samples — p=.05
Phase 3 N=28 A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Post Partum Depression
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 3; 5 Participants
N/A N=68 Residential MapTrek- Increasing Physical Activity Among Older Adults in a Residential-Living
Sedentary Behavior
Primary: Physical Activity — 6681 Steps/day — p=<0.01
Phase 2 N=243 A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 — 41.5; 46.8; 43.4 percentage of participants — p=0.422
Phase 2 N=32 Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma
Multiple Myeloma
Primary: The Maximum Tolerated Dose of Bortezomib (MTD) — 1.6 mg/m2 of bortezomib
Phase 1 N=59 Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
Alcohol Drinking
Primary: Occupancy of KOR by NTX and Drinking — 92 % Occupancy
Phase 2 N=68 Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
Prostate Adenocarcinoma · Stage IIB Prostate Cancer AJCC v8 · Stage IIC Prostate Cancer AJCC v8
Primary: The Number of Participants With Rate of Pathologic Stage =< pT2N0 at Prostatectomy — 13; 12 Participants
Phase 4 N=60 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection
HIV Infections
Primary: Symptom Score — 10; 8 units on a scale — p=0.45
Phase 2 N=331 The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 6 — 28.0; 22.8; 8.3 percentage of participants…